Vancomycin for MRSA: Can Dose Monitoring Protect

What did COVID-19 reveal about resistant hospital infections?

The CDC's COVID-19 and antimicrobial resistance overview, updated in February 2025, describes historical damage to infection control. Across seven resistant pathogens, hospital-onset infections and associated deaths each increased by at least 15% between 2019 and 2020. Longer hospital stays, greater use of invasive devices, staffing pressures and disrupted prevention practices contributed to conditions in which resistant organisms could spread. Antibiotics were also frequently prescribed to hospitalized COVID-19 patients, although they do not treat the virus itself. [CDC pandemic overview](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html).

Recovery differed by organism. In its subsequent analysis, CDC reported that rates for five of six tracked resistant bacterial hospital-onset infections remained above their pre-pandemic levels in 2022; methicillin-resistant Staphylococcus aureus, or MRSA, was the exception. These findings describe population trends through 2022 and cannot establish today's risk for an individual patient. A practical implication for treatment is that infection prevention and careful antibiotic management remain complementary priorities. [CDC surveillance update](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/update-2022.html).

How does exposure-based vancomycin monitoring work?

Vancomycin monitoring traditionally relied on the trough: the blood concentration immediately before another dose. The 2020 consensus guideline from ASHP, IDSA, PIDS and SIDP recommends using the area under the concentration-time curve, or AUC, for serious MRSA infections. This estimates exposure across a full day, providing a more complete dosing target than a trough concentration alone.

The recommended 24-hour AUC target is 400–600 mg·h/L when the organism's minimum inhibitory concentration, a measure of susceptibility, is assumed to be 1 mg/L. The guideline recommends achieving this exposure within 24–48 hours. These are clinician-managed treatment targets, supported mainly by evidence from serious MRSA infections, particularly complicated bloodstream infections. Applying them to mild infections or different bacteria requires caution. [Vancomycin monitoring guideline](https://www.idsociety.org/practice-guideline/vancomycin/).

How strong is the evidence that AUC monitoring reduces kidney injury?

A 2022 systematic review and meta-analysis in Pharmacotherapy combined 10 studies involving 4,231 patients. It found that AUC-guided vancomycin dosing was associated with a lower incidence of acute kidney injury than trough-guided dosing. The finding supports efforts to avoid unnecessary drug exposure while maintaining treatment, but it does not mean that kidney injury can always be prevented.

The limitations matter. The included studies involved adults who were not critically ill, and their retrospective designs left potential confounding: differences between patient groups or care practices could have influenced the results. Findings also varied with the definition of kidney injury used. The authors therefore graded the evidence as low certainty. The study supports a treatment-safety strategy, while leaving uncertainty about the exact benefit in intensive care and other populations. It did not establish that AUC monitoring reduces antimicrobial resistance across hospitals. [Abdelmessih and colleagues, Pharmacotherapy](https://pmc.ncbi.nlm.nih.gov/articles/PMC9481691/).